Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB097 with pembrolizumab in melanoma with primary resistance to anti-PD1
NCT06540391Phase 1Active, not recruiting
- Sponsor
- Microbiotica
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of MB097 in melanoma (3 arms), sponsored by Microbiotica. Primary endpoint: Safety and tolerability of MB097 in combination with pembrolizumab. Started Aug 2024; status: active, not recruiting.
02
Drugs
MB097
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06540391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540391.